Contact information

Ari Ristimäki
M.D., Ph.D.
Biomedicum Helsinki
PO Box 63
(Haartmaninkatu 8)
FI-00014 University of Helsinki, Finland
Tel. +358 2941 25588
Fax. +358 2941 26700
Email: firstname.surname @helsinki.fi


Affiliations

Translational Research in Inflammation and Cancer

Translational research combines molecular medicine and clinical research in order to discover novel means to treat diseases. Our goal is to study the connection of inflammation in carcinogenesis and whether anti-inflammatory agents can suppress tumor growth. Human trials and experimental animal studies indicate that the use of nonsteroid anti-inflammatory drugs (NSAIDs) reduces risk of cancer. The best-known target of NSAIDs is cyclooxygenase (COX), and our results show that expression of COX-2 isoform is elevated in human malignancies and that inhibition of COX-2 suppresses tumor growth in experimental tumor models. Our clinical investigations are targeted to evaluation of the prognostic significance of COX-2 expression in human cancer materials. Molecular mechanisms that lead to overexpression of COX-2 are investigated in cultured cancer cells and in in vivo models. The ultimate goal of our work is to better understand the role of COX-2 in human carcinogenesis, which hopefully will help to target the use of COX-2 selective drugs to those cancer patients, who will most likely benefit from this treatment.